Allergy Immunotherapies Market

Allergy Immunotherapies Market Size:

The global allergy immunotherapies market size reached US$ 3.1 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.7 Billion by 2032, exhibiting a growth rate (CAGR) of 8.7% during 2024-2032. The market is propelled by the rising prevalence of allergic conditions, increasing awareness about immunotherapy as an effective treatment for allergies, significant developments in immunotherapy treatments and technologies, favorable government policies and funding for allergy research, and customized medicine and tailored treatment approaches.

Allergy Immunotherapies Market Analysis:

• Major Market Drivers: Rapidly increasing prevalence of allergic conditions, significant developments in immunotherapy treatments and technologies, and supportive government policies and funding for allergy research.
• Key Market Trends: Some of the key market trends include increasing popularity of customized medicine and personalized treatment approaches, rapid expansion of treatment indications in order to include a wide range of allergies and increasing strategic collaborations and partnerships among biotech and pharmaceutical companies, thereby driving the allergy immunotherapies market growth.
• Geographical Trends: The high prevalence of allergic diseases, rising healthcare expenditure, and robust healthcare infrastructure are leading to a high rise in the allergy immunotherapies market demand in the North American region.
• Competitive Landscape: ALK-Abello A/S, Allergy Therapeutics, Stallergenes Greer, HAL Allergy Holding B.V., DBV Technologies, Merck KGaA, Aimmune Therapeutics, Circassia Pharmaceuticals, Anergis SA, and Biomay AG, are among some of the key players in the allergy immunotherapies industry. 
• Challenges and Opportunities: Some of the challenges include high costs of treatment, restricted awareness in developing regions, and viability in treatment response. Whereas, significant technological developments, rapid expansion into emerging markets, and integration of digital tools are some of the major opportunities.
   

Allergy Immunotherapies Market Trends:

Increasing Incidence of Allergic Disorders

The global increase in the prevalence of allergic diseases is a major driver of the allergy immunotherapies market. Allergies, such as allergic rhinitis, asthma, and food allergies, have become more common worldwide, particularly in industrialized countries. Environmental factors, such as pollution and changes in lifestyle and dietary habits, have contributed to this increase. According to the WORLD HEALTH ORGANIZATION (WHO), asthma affected almost 262 million individuals in 2019 and caused 455000 deaths. This growing patient population demands effective long-term treatment solutions, thereby boosting the demand for allergy immunotherapies which promise desensitization to allergens and a potential reduction in the severity of allergic reactions.

Significant Advancements in Treatment Technologies

Technological advancements in allergy immunotherapies have revolutionized the approach and effectiveness of treatments for allergic diseases. Innovations such as peptide-based immunotherapies and recombinant allergens mark a significant departure from traditional methods, offering a more personalized and precise treatment pathway. Peptide-based therapies, for instance, utilize small peptides that represent parts of the allergen proteins to induce tolerance without triggering a full immune response, thereby minimizing the risk of severe reactions that are sometimes seen with whole-allergen immunotherapies. According to the IMARC GROUP, the global peptide therapeutics market has reached US$ 42.8 Billion in 2023, and is projected to reach US$ 86.9 Billion by 2032, exhibiting a CAGR of 7.9% during 2024-2032. Similarly, recombinant allergens, which are genetically engineered to mimic natural allergens, provide a purer and more consistent treatment option that can be finely tuned for dosage and formulation. These technological breakthroughs have improved the safety profile of immunotherapies and have also enhanced their efficacy, leading to higher success rates in desensitizing patients to allergens.

Regulatory and Reimbursement Landscape

The regulatory and reimbursement landscape plays a crucial role in shaping the allergy immunotherapies market, significantly influencing both the development and the widespread adoption of new treatments. Recent years have seen a positive trend in this regard, with regulatory bodies such as the U.S. Food and Drug Administration (FDA) granting approvals to innovative treatments such as sublingual immunotherapy tablets. These approvals are pivotal because they validate the safety and efficacy of new therapies and facilitate broader market access. Concurrently, there has been a marked improvement in insurance coverage for these therapies. This expansion in coverage is crucial for patients, as it alleviates the financial burden associated with long-term allergy management, making these advanced therapies more feasible for a larger number of individuals.

Allergy Immunotherapies Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the global and regional levels for 2024-2032. Our report has categorized the market based on treatment type, allergy type, and distribution channel.

Breakup by Treatment Type:

• Subcutaneous Immunotherapy (SCIT)
• Sublingual Immunotherapy (SLIT)
   

Subcutaneous immunotherapy (SCIT) accounts for the majority of the allergy immunotherapies market share

The report has provided a detailed breakup and analysis of the market based on the treatment type. This includes subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT). According to the report, subcutaneous immunotherapy represented the largest segment.

The global allergy immunotherapies industry is dominated by subcutaneous immunotherapy due to several compelling factors. SCIT has a long-standing track record of efficacy and safety, supported by extensive clinical research and decades of use in treating allergic diseases such as hay fever, allergic asthma, and stings from insects. This history has established SCIT as a trusted standard of care among healthcare providers and patients alike. Moreover, the effectiveness of SCIT in reducing allergy symptoms and potentially modifying the natural course of allergic diseases contributes significantly to its dominance. The treatment involves injecting small doses of an allergen under the skin to boost tolerance to the allergen over time, thereby decreasing symptoms on subsequent exposure.

Breakup by Allergy Type:

• Allergic Rhinitis
• Asthma
• Food Allergy
• Venom Allergy
• Others
   

Allergic rhinitis holds the largest share in the industry

A detailed breakup and analysis of the market based on allergy type have also been provided in the allergy immunotherapies report. This includes allergic rhinitis, asthma, food allergy, venom allergy, and others. According to the report, allergic rhinitis accounted for the largest market share.

Allergic rhinitis is the largest segment in the market breakup by allergy type primarily due to its high prevalence globally. Often referred to as hay fever, allergic rhinitis affects a significant portion of the population, characterized by symptoms such as sneezing, stuffy or runny nose, itching, and watery eyes, which are triggered by allergens such as pollen, dust mites, and pet dander. The chronic nature of allergic rhinitis and its significant impact on quality of life also contribute to the urgency and demand for long-term treatment approaches. Furthermore, the increasing environmental pollution and changes in lifestyle that elevate the risk of developing allergic conditions amplify the need for allergy immunotherapies. As a result, allergic rhinitis commands a significant share of the market due to the large patient pool requiring ongoing management and treatment of this pervasive condition, thereby contributing heavily toward the allergy immunotherapies market revenue.

Breakup by Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
   

Hospital pharmacy represent the leading market segment 

The allergy immunotherapies market research report has provided a detailed breakup and analysis of the market based on the distribution channel. This includes hospital pharmacy retail pharmacy, and online pharmacy. According to the report, hospital pharmacy represented the largest segment.

Hospital pharmacy is the largest segment in the market breakup by distribution channel for several key reasons. Primarily, hospital pharmacies are pivotal in administering and managing complex treatments that require close medical supervision, such as allergy immunotherapies, which often involve initial dosing under medical observation to monitor for adverse reactions. Hospitals are equipped with the necessary infrastructure and expertise to handle such specialized treatments, making them a natural hub for dispensing these therapies. Furthermore, hospitals serve a critical role in patient care, offering integrated services that include diagnosis, treatment, and follow-up in a single location, which is particularly important for treatments that require ongoing adjustments and monitoring. Additionally, the consolidation of healthcare services within hospitals allows for streamlined treatment protocols and better management of healthcare resources, thus creating a positive allergy immunotherapies market outlook.

Breakup by Region:

• Europe
• North America
• Asia Pacific
• Middle East and Africa
• Latin America
   

Europe leads the market, accounting for the largest allergy immunotherapies market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America, Asia Pacific, Europe, Latin America, and the Middle East and Africa. According to the report, Europe was the largest market for allergy immunotherapies.

Europe holds the distinction of being the largest segment in the market breakup by region for allergy immunotherapies, primarily due to a combination of high allergy prevalence, advanced healthcare infrastructure, and proactive regulatory policies. The region has a notably high incidence of allergic disorders among its population, including respiratory allergies such as hay fever and asthma, which drives a strong demand for effective and long-term treatment solutions such as immunotherapy. European countries benefit from robust healthcare systems that are well-equipped to administer advanced treatments and are supported by comprehensive insurance coverage that often includes allergy immunotherapies. Moreover, Europe has been at the forefront in the adoption of innovative medical practices, with several European countries pioneering the research and development of new immunotherapy treatments.

Competitive Landscape:

• The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the allergy immunotherapies industry include ALK-Abello A/S, Allergy Therapeutics, Stallergenes Greer, HAL Allergy Holding B.V., DBV Technologies, Merck KGaA, Aimmune Therapeutics, Circassia Pharmaceuticals, Anergis SA, and Biomay AG.
  
  (Please note that this is only a partial list of the key players, and the complete list is provided in the report.)
   
• Key players are in the allergy immunotherapies industry have been pivotal in driving its growth through a series of strategic initiatives aimed at innovation, expansion, and education. Allergy immunotherapies companies invest heavily in research and development to bring forth new and more effective immunotherapy options, focusing on reducing side effects and increasing the efficacy of treatments. For instance, advancements in sublingual immunotherapies and the development of peptide-based treatments reflect these efforts, offering patients less invasive and more convenient treatment regimens. Moreover, major players are expanding their geographic and market presence through mergers, acquisitions, and partnerships with smaller biotech firms, enhancing their capabilities and reaching broader patient populations. Additionally, in accordance with the allergy immunotherapies market forecast, these companies play a crucial role in patient and practitioner education, conducting seminars, workshops, and online campaigns to increase awareness about the benefits and advancements in allergy immunotherapies.

Latest News: 

• October 3, 2023: The Royal Brompton Hospital in London is starting a clinical trial for Angany vaccine, ANG-101, to treat cat allergy. The vaccine is a therapeutic approach derived from eBioparticle-potentiated immunotherapy technology.

Allergy Immunotherapies Market Report Scope:

Key Benefits for Stakeholders:

• IMARC’s industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the allergy immunotherapies market from 2018-2032.
• The research report provides the latest information on the market drivers, challenges, and opportunities in the global allergy immunotherapies market.
• The study maps the leading, as well as the fastest-growing, regional markets.
• Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the allergy immunotherapies industry and its attractiveness.
• The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.